The FDA has approved a number of gadolinium-based contrast agents. These contrast agents include Magnevist, MultiHance, Omniscan, OptiMARK, and ProHance. 

While the use of these drugs has been associated with NSF, they still have FDA approval. One reason for maintaining this approval is that medical reports have not gathered enough information about the correlation between gadolinium and NSF. 

If you have beeen diagnosed with NSF and been exposed to a gadolinium-based contrast agent, contact the gadolimium lawyers of Williams Kherkher at 800-761-3187.

An FDA-appointed panel has ruled that restrictions should be placed on the use of gadolinium contrast agents (commonly used in medical imaging scans) after convincing evidence has linked the agents to a potentially fatal skin-hardening disease called nephrogenic systemic fibrosis (NSF). Sources say that NSF is a progressive disease that can cause the skin to thicken and harden in the arms, legs, and extremities.

While the FDA does not have to follow the advice of it's appointed panels, sources say that a panel recommendation often goes a long way toward implementing new regulations. 

If you or someone you love has suffered NSF or other health problems caused by gadolinium contrast agents, contact the NSF attorneys of Williams Kherkher at 800-761-3187 today.